Protocol Ledger

NCT05532800 · Phase III · COMPLETED

The Efficacy and Safety of JS002 PFS and AI in Patients With Primary Hypercholesterolemia and Mixed Hyperlipidemia

Interventional Phase III clinical trial protocol NCT05532800 sponsored by Shanghai Junshi Bioscience Co in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-02-28 Enrollment: 255 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05532800
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)255 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05532800
Protocol FieldVerified Registry Value
NCT IdentifierNCT05532800
Consolidated Lead SponsorShanghai Junshi Bioscience Co
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment255 participants (ACTUAL)
Registered Start Date2022-02-28
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05532800
Hospital Research SiteLocationSite Profile
Peking University Third HospitalBeijing, ChinaOpen Hospital Dossier ->
China-Japan Friendship HospitalBeijing, ChinaOpen Hospital Dossier ->
The First Affiliated Hospital Of Fujian Medical UniversityFuzhou, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI